Medical Industry Feature

The brain is constantly changing as a result of experience, stress, emotional processing, learning, and memory.1 And neuroplasticity adds another layer to these approaches by focusing on what’s actually changing in the brain.2 Tune in with Dr. Charles Turck as he speaks with Dr. Madhukar Trivedi, Founding Director of the Center for Depression Research and Clinical Care and Chief of the Division of Mood Disorders at the University of Texas Southwestern Medical Center in Dallas, Texas.

References:

1. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63-77.
2. Mateos-Aparicio P, Rodriguez-Moreno A. The impact of studying brain plasticity. Front Cell Neurosci. 2019;13:66.

On this episode of Advances in Care, host Erin Welsh sits down with Dr. Thomas Bottiglieri, Chief of the Primary Care Sports Medicine Division at NewYork-Presbyterian and Columbia, to discuss the evolving landscape of concussion care—from prevalence to emerging diagnostic breakthroughs.

With over 2 million estimated concussions occurring annually in the United States and many of them affecting young athletes, Dr. Bottiglieri and his colleagues have sought to develop a more accurate and accessible way to objectively diagnose concussion. While a single injury may not cause long-term issues, research shows that repeated head trauma—and lack of proper care—can lead to premature neurodegeneration.

During their research to improve diagnostic measures, Dr. Bottiglieri and his team discovered a biomarker associated with severe concussions: a subtle tremor of the head and neck that becomes amplified when a concussed patient tries to visually focus on a target.

This discovery led to the development of ProScope, an innovative eye-tracking software tool that measures head and neck stability and can detect the diagnostic biomarker with over 80% sensitivity. With the advent of these tools, clinicians can now, for the first time, objectively measure concussion. A former competitive athlete himself, Dr. Bottiglieri hopes that the ProScope tool …

Learn how Dr. Pierre Elias and his team at NewYork-Presbyterian and Columbia have established a deep learning lab called CRADLE, which uses basic medical imaging, EKGs, and echocardiograms to build advanced AI models that help identify all forms of structural heart disease, including cardiac amyloidosis and valvular regurgitation. These tools not only improve screening access but enable early detection.

© 2026 NewYork-Presbyterian

Starting with the presence of a prior fracture, advancing age, and bone mineral density, there are numerous factors that increase the risk of fracture in postmenopausal women.1 But despite these common predictors, treatment rates of osteoporosis in postmenopausal women have consistently remained low.2 For instance, in the last decade, less than 10% of women aged 50 years and older have received treatment for their osteoporosis.2 To help address these unmet needs, Dr. Jennifer Caudle speaks with Dr. Felicia Cosman about best practices for diagnosing and treating postmenopausal osteoporosis patients who are at a very high risk of fracture. Dr. Cosman is a Professor of Medicine Emerita at Columbia University Vagelos College of Physicians and Surgeons in New York.

References:

1. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002;288:1889-1897.
2. Data on file, Amgen; 2024.

Nearly half of patients living with dementia due to Alzheimer’s disease will experience agitation during the course of illness.1 In June 2025, expert panel recommendations on identifying and managing agitation in Alzheimer’s dementia were published in Postgraduate Medicine. Learn more about these recommendations as Dr. Charles Turck, Dr. George Grossberg, and Dr. Angela Sanford explore how clinicians can implement them in practice. Dr. Grossberg is the Inaugural Henry and Amelia Nasrallah Endowed Professor as well as the Director of the Division of Geriatric Psychiatry and Behavioral Neuroscience at the Saint Louis University School of Medicine. Dr. Sanford is a Professor in the Division of Geriatric Medicine in the Department of Internal Medicine at the Saint Louis University School of Medicine.

Drs. Grossberg and Sanford are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. The expert panel and subsequent publication were sponsored by Otuska and Lundbeck -- not an independent entity.

References:

1. Grossberg GT, Sanford A, Montano CB, et al. A US-based practitioner's guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer's dementia - recommendations of an expert, multispecialty advisory panel. Postgrad Med. 2025;137(6):469–485.

While anti-VEGF therapy can deliver vision gains with consistent, frequent injections in clinical trials, it may be challenging to sustain this in real-world practice.1 Ocular gene therapy could be a potential option for patients with neovascular age-related macular degeneration if approved. With this approach, transgenes are delivered to the eye by adeno-associated viruses (AAVs).2-4 Learn more with Drs. Courtney Crawford and Raj Maturi, who shared their perspectives on investigational gene therapy, patient conversations, and surgical considerations at the 2025 American Academy of Ophthalmology annual meeting in Orlando, Florida.

Dr. Crawford is a board-certified retina specialist and founder of Star Retina in Burleson, Texas. He previously served for 10 years as a physician in the U.S. Army, where he attained the rank of Lieutenant Colonel. Dr. Maturi is a board-certified retina specialist at the Midwest Eye Institute and founder of Retina Partners Midwest in Carmel, Indiana, where he focuses on macular, retina, and vitreous care.

References:

1. Weng CY, Singh RP, Gillies MC, Regillo CD. Optimizing visual outcomes in patients with neovascular age-related macular degeneration: the potential value of sustained anti-VEGF therapy. Ophthalmic Surg Lasers Imaging Retina. 2023;54:654–659.
2. Petrich J, Marchese D, Jenkins C, Storey M, Blind J. …

For the latest insights on tau and neurodegeneration biomarkers in Alzheimer’s disease (AD), tune in to this recorded presentation featuring Doctor Michelle Mielke and Professor Henrik Zetterberg. Together, they delve into the role of tau in AD, exploring the ‘tau cascade’, the current use of tau and neurodegeneration biomarkers in tracking disease progression, and how the AD biomarker landscape may evolve over time. Doctor Mielke is a Professor of Epidemiology and Neurology at the Wake Forest University School of Medicine, and Professor Zetterberg is a Professor of Neurochemistry at the University of Gothenburg.

To learn more about tau in Alzheimer’s disease, explore the Know Tau medical education platform. Know Tau is created and funded by Biogen and is intended for healthcare professionals only.

Lauren Osborne, M.D., a reproductive psychiatrist at NewYork-Presbyterian and Weill Cornell Medicine and vice chair for clinical research for the Department of Obstetrics and Gynecology, discusses her research into the biological basis of postpartum depression. In a recent study, Dr. Osborne and her team were the first to analyze the entire metabolic pathway of progesterone, measuring both positive and negative allosteric modulators of the GABAA receptor throughout pregnancy and ultimately identifying a potential biomarker to predict risk. They are continuing to study and build upon these findings, with the goal of enabling better prediction and treatment options to address, or even prevent, postpartum depression.

© 2026 NewYork-Presbyterian

The prevalence of dementia is projected to almost double every 20 years.1 Alzheimer’s disease (AD) is the most common cause of dementia,2 making early diagnosis and management increasingly important. Based on our current understanding of its pathology, AD is an amyloid driven tauopathy3 with biomarker changes occurring years before clinical symptoms appear.4 Learn more with this webinar featuring Dr Niklas Mattsson-Carlgren, Associate Professor at Lund University as he explores the relationship between amyloid beta and tau, the correlation between pathology and clinical symptoms, and biomarker progression across the AD continuum.

To learn more about tau in Alzheimer’s disease, explore the Know Tau medical education platform. Know Tau is created and funded by Biogen and is intended for healthcare professionals only.

References:

1. Alzheimer’s Disease International. Numbers of people with dementia worldwide. Available from: https://www.alzint.org/resource/numbers-of-people-with-dementia-worldwide/ (Accessed June 2025)
2. Alzheimer’s Association. Alzheimer’s disease facts and figures. Available from: https://www.alz.org/alzheimers-dementia/facts-figures (Accessed June 2025)
3. Aksman LM, et al. Brain 2023;146:4935–4948
4. Jack CR Jr, et al. Alzheimers Dement 2018;14:535–562

There’s been recent progress with antibody-drug conjugates (ADCs) for HER2-negative breast cancers,1-3 and most recently, patients with metastatic HR+ HER2- breast cancer. The phase III TROPION-Breast01 study examined the efficacy and safety of datopotamab deruxtecan-dInk (Dato-DXd) compared to investigator’s choice single-agent chemotherapy, resulting in the approval of this agent in January 2025. Joining Dr. Charles Turck to discuss Dato-DXd for patients with HR-positive, HER2-negative metastatic breast cancer, data from the TROPION-Breast01 trial, and strategies for managing select adverse reactions with this therapy are Dr. Komal Jhaveri and Nurse Vanessa Soto-Romano. Dr. Jhaveri is a breast medical oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center in New York, and Nurse Soto-Romano is a Clinical Trials Nurse, also at Memorial Sloan Kettering Cancer Center in New York.

Dr. Komal Jhaveri
Consultant/advisory board role: Novartis, Pfizer, Genentech, Eisai, AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Menarini/Stemline, Gilead, Scorpion Therapeutics, Bicycle Therapeutics, Olema Pharmaceuticals, Lilly/Loxo Oncology, Merck Pharmaceuticals, Zymeworks, Halda Therapeutics, Arivinas and Rayzebio
Research Funding support to the Institution: Novartis, Genentech, AstraZeneca, Pfizer, Lilly/Loxo Oncology, Zymeworks, Gilead, PUMA Biotechnology, Merck Pharmaceuticals, Scorpion Therapeutics, Rayzebio, Eisai, Bicycle Therapeutics, Bridge Bio Oncology Therapeutics, and Blueprint Medicines.

Nurse Soto-Romano
Consultant/advisory board role: AstraZeneca …